Abstract:Remimazolam is a novel ultrashort-acting sedative-hypnotics of benzodiazepines, which metabolized by tissue non-specific cholinesterase. It has the character that hardly influence on hemodynamics and respiratory function. With rapid metabolism, it has a strong controllability and doesnt accumulation after long-time infusion. Moreover, it provides a rapid recovery after anesthesia that can be antagonized by flumazenil specifically. Nowadays, remimazolam is used in procedure sedation in numerous situations of anesthesia. This article focuses on elderly, hepatic and renal impairment, pediatrics, obesity, and obstetrics patients, aims at providing references in clinical applications.